Article Text

Original article
Exome sequencing identifies mutations in the gene TTC7A in French-Canadian cases with hereditary multiple intestinal atresia
  1. Mark E Samuels1,
  2. Jacek Majewski2,
  3. Najmeh Alirezaie2,
  4. Isabel Fernandez1,3,
  5. Ferran Casals1,
  6. Natalie Patey1,4,
  7. Hélène Decaluwe1,5,
  8. Isabelle Gosselin6,
  9. Elie Haddad1,3,5,
  10. Alan Hodgkinson1,
  11. Youssef Idaghdour1,
  12. Valerie Marchand1,5,
  13. Jacques L Michaud1,5,
  14. Marc-André Rodrigue6,7,
  15. Sylvie Desjardins6,
  16. Stéphane Dubois6,
  17. Francoise Le Deist1,3,
  18. Philip Awadalla1,5,
  19. Vincent Raymond6,7,
  20. Bruno Maranda8
  1. 1Centre de Recherche du CHU Ste-Justine, University of Montreal, Montreal, Quebec, Canada
  2. 2Department of Human Genetics, McGill University, Montreal, Quebec, Canada
  3. 3Department of Microbiology and Immunology, University of Montreal, Montreal, Quebec, Canada
  4. 4Department of Pathology, University of Montreal, Montreal, Quebec, Canada
  5. 5Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
  6. 6Department of Neurosciences, Centre de recherche du CHU de Québec, Université Laval, Québec City, Quebec, Canada
  7. 7Département de Médecine Moléculaire, Université Laval, Québec City, Quebec, Canada
  8. 8Medical Genetics Service, University of Sherbrooke, Sherbrooke, Quebec, Canada
  1. Correspondence to Bruno Maranda, Medical Genetics Service, University of Sherbrooke, Sherbrooke, Quebec, Canada J1K 2R1; Bruno.Maranda{at}USherbrooke.ca

Abstract

Background Congenital multiple intestinal atresia (MIA) is a severe, fatal neonatal disorder, involving the occurrence of obstructions in the small and large intestines ultimately leading to organ failure. Surgical interventions are palliative but do not provide long-term survival. Severe immunodeficiency may be associated with the phenotype. A genetic basis for MIA is likely. We had previously ascertained a cohort of patients of French-Canadian origin, most of whom were deceased as infants or in utero. The goal of the study was to identify the molecular basis for the disease in the patients of this cohort.

Methods We performed whole exome sequencing on samples from five patients of four families. Validation of mutations and familial segregation was performed using standard Sanger sequencing in these and three additional families with deceased cases. Exon skipping was assessed by reverse transcription-PCR and Sanger sequencing.

Results Five patients from four different families were each homozygous for a four base intronic deletion in the gene TTC7A, immediately adjacent to a consensus GT splice donor site. The deletion was demonstrated to have deleterious effects on splicing causing the skipping of the attendant upstream coding exon, thereby leading to a predicted severe protein truncation. Parents were heterozygous carriers of the deletion in these families and in two additional families segregating affected cases. In a seventh family, an affected case was compound heterozygous for the same 4bp deletion and a second missense mutation p.L823P, also predicted as pathogenic. No other sequenced genes possessed deleterious variants explanatory for all patients in the cohort. Neither mutation was seen in a large set of control chromosomes.

Conclusions Based on our genetic results, TTC7A is the likely causal gene for MIA.

  • Gastroenterology
  • Genetics
  • Developmental
  • Molecular genetics

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: